Q3 FY2025 · ended Mar 31, 2025 · Revenue $15.00M, +2163.4% YoY · Filed May 15, 2026
Neuphoria Therapeutics Inc. (NEUP) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$15.00M
+2163.4% vs prior quarter
Net income
$-4.90M
+44.8% vs year-ago quarter
Operating cash flow
$1.21M
+133.9% vs year-ago quarter
Free cash flow
—
EPS
$-0.91
+80.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
5.41M
+129.5% vs year-ago quarter
Net cash
$19.44M
Q3 FY2026
Operating margin
79.8%
Q3 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NEUP (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Burlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1191070
- Former names
- BIONOMICS LIMITED/FI (until Dec 23, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q4 FY2025 Jun 30, 2025 |
Q3 FY2025 Mar 31, 2025 |
Q2 FY2025 Dec 31, 2024 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $15.0M | $662,715 |
| Operating income | -$5.5M | -$1.2M | -$5.8M | $12.0M | -$3.7M |
| Net income | -$4.9M | -$505,063 | -$8.9M | $11.3M | -$1.9M |
| Diluted EPS | -$0.91 | -$0.09 | -$4.67 | $6.55 | -$1.79 |
| Operating cash flow | $1.2M | -$13.6M | -$3.6M | $11.5M | -$3.4M |
| Total assets | $28.7M | $34.8M | $28.6M | $30.7M | $18.2M |
| Total liabilities | $4.1M | $5.4M | $9.6M | $4.7M | $4.4M |
| Stockholders' equity | $24.6M | $29.4M | $19.0M | $26.0M | $13.7M |
| Cash and investments | $19.9M | $19.4M | $14.2M | $17.0M | $4.3M |
| Total debt | — | $0 | $116,314 | $141,060 | $168,310 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Oct 23, 2026 | Oct 23, 2026 |
| 10-K | Annual report | Sep 18, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Change in control, Regulation FD disclosure
|
Jul 24, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Other events
|
May 26, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Feb 17, 2026 | Dec 31, 2025 |
All 420 Neuphoria Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.